Biotech and Early Engagement Considerations: What Companies Must Consider When Developing an Asset

Biotech & Early Engagement Considerations: What Companies Must Consider When Developing an Asset

Emerging biotech companies are a significant and burgeoning sector of the pharmaceutical development market. These companies may require unique and specialized expertise to guide them through asset development. There are a multitude of considerations when evaluating an asset for development, including the vision for the asset, development and continuum capabilities, and global versus local development.

In this whitepaper, you will learn:

• How to navigate the complexities of asset development
• Overall considerations emerging biotech companies can be discussing with development partners
• What makes a successful partner who can assist a small biotech company with necessary development strategies

This is the first in a series of white papers that will help outline considerations for asset development. Lead the pack in all steps of the development process with this guide.

EBD Group Inc., 3150 Pio Pico Drive, Suite 201, Carlsbad, CA, 92008

Terms and Conditions | Privacy Policy

Country *

First Name *

Last Name *

Email *

Zip Code *

Company Name *

Job Title *

Please tick these boxes if you do not wish to receive marketing information relevant to you from Xconomy

via Email

via Telephone

via Post

Please tick this box if you do not wish to be added to our mailing list for related opportunities from our third party partners

DOWNLOAD NOW: